Phospho-Tuberin/TSC2 (Thr1462) Antibody (Rabbit mAb) [F15L14]

Catalog No.: F3343

    Application: Reactivity:
    • Lane 1: SH-SY5Y, Lane 2: SH-SY5Y (Okadaic Acid, 1uM, Calyculin A, 200nM, 60 min), Lane 3: SH-SY5Y (Okadaic Acid, 1uM, Calyculin A, 200nM, 60 min; phosphatase treated)
    1/

    当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

    代表番号: 045-509-1970|電子メール:sales@selleck.co.jp

    キーポイント

    WB
    SDS-PAGE の分離ゲルの推奨濃度:5%
    転写条件(ウェット): 250 mA, 180 min

    使用情報

    Dilution
    1:1000 - 1:10000
    1:50 - 1:100
    Application
    WB, IHC
    Source
    Rabbit Monoclonal Antibody
    Reactivity
    Mouse, Human
    Storage Buffer
    PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3
    Storage (from the date of receipt)
    -20°C (avoid freeze-thaw cycles), 2 years
    Predicted MW Observed MW
    201 kDa 180 kDa
    *なぜ予測分子量と実際の分子量が異なるのか?
    下記の原因により、実際の分子量が予測と異なる:タンパク質の翻訳後修飾(リン酸化/糖鎖付加),スプライシングバリアント,イソフォーム,相対的な電荷,ポリマー。
    ポジティブコントロール Human liver tissue; NIH/3T3 cells (insulin treated); SH-SY5Y cells (Okadaic Acid, 1uM; Calyculin A, 200nM, 60 min)
    ネガティブコントロール NIH/3T3 cells; SH-SY5Y cells

    プロトコール

    WB
    Experimental Protocol:
     
    Sample preparation
    1. Tissue: Lyse the tissue sample by adding an appropriate volume of ice-cold RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail),and homogenize the tissue at a low temperature or lyse it by sonication on ice, then incubate on ice for 30 minutes.
    2. Adherent cell: Aspirate the culture medium and wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    3. Suspension cell: Transfer the culture medium to a pre-cooled centrifuge tube. Centrifuge and aspirate the supernatant. Wash the cells with ice-cold PBS twice. Lyse the cells by adding an appropriate volume of RIPA/NP-40 Lysis Buffer (containing Protease Inhibitor Cocktail, Phosphatase Inhibitor Cocktail) , sonicate to lyse the cells, and incubate on ice for 30 minutes.
    4. Place the lysate into a pre-cooled microcentrifuge tube. Centrifuge at 4°C for 15 min. Collect the supernatant;
    5. Remove a small volume of lysate to determine the protein concentration;
    6. Combine the lysate with protein loading buffer. Boil 20 µL sample under 95-100°C for 5 min. Centrifuge for 5 min after cool down on ice.
     
    Electrophoretic separation
    1. According to the concentration of extracted protein, load appropriate amount of protein sample and marker onto SDS-PAGE gels for electrophoresis. Recommended separating gel (lower gel) concentration: 5%. Reference Table for Selecting SDS-PAGE Separation Gel Concentrations
    2. Power up 80V for 30 minutes. Then the power supply is adjusted (110 V~150 V), the Marker is observed, and the electrophoresis can be stopped when the indicator band of the predyed protein Marker where the protein is located is properly separated. (Note that the current should not be too large when electrophoresis, too large current (more than 150 mA) will cause the temperature to rise, affecting the result of running glue. If high currents cannot be avoided, an ice bath can be used to cool the bath.)
     
    Transfer membrane
    1. Take out the converter, soak the clip and consumables in the pre-cooled converter;
    2. Activate PVDF membrane with methanol for 1 min and rinse with transfer buffer;
    3. Install it in the order of "black edge of clip - sponge - filter paper - filter paper - glue -PVDF membrane - filter paper - filter paper - sponge - white edge of clip";
    4. The protein was electrotransferred to PVDF membrane. ( 0.45 µm PVDF membrane is recommended ) Reference Table for Selecting PVDF Membrane Pore Size Specifications
    Recommended conditions for wet transfer: 250 mA, 180 min.
    ( Note that the transfer conditions can be adjusted according to the protein size. For high-molecular-weight proteins, a higher current and longer transfer time are recommended. However, ensure that the transfer tank remains at a low temperature to prevent gel melting.)
     
    Block
    1. After electrotransfer, wash the film with TBST at room temperature for 5 minutes;
    2. Incubate the film in the blocking solution ( recommending 5% BSA solution) for 1 hour at room temperature;
    3. Wash the film with TBST for 3 times, 5 minutes each time.
     
    Antibody incubation
    1. Use 5% skim milk powder to prepare the primary antibody working liquid (recommended dilution ratio for primary antibody 1:1000), gently shake and incubate with the film at 4°C overnight;
    2. Wash the film with TBST 3 times, 5 minutes each time;
    3. Add the secondary antibody to the blocking solution and incubate with the film gently at room temperature for 1 hour;
    4. After incubation, wash the film with TBST 3 times for 5 minutes each time.
     
    Antibody staining
    1. Add the prepared ECL luminescent substrate (or select other color developing substrate according to the second antibody) and mix evenly;
    2. Incubate with the film for 1 minute, remove excess substrate (keep the film moist), wrap with plastic film, and expose in the imaging system.
    IHC
    Experimental Protocol:
     
    Deparaffinization/Rehydration
    1. Deparaffinize/hydrate sections:
    2. Incubate sections in three washes of xylene for 5 min each.
    3. Incubate sections in two washes of 100% ethanol for 10 min each.
    4. Incubate sections in two washes of 95% ethanol for 10 min each.
    5. Wash sections two times in dH2O for 5 min each.
    6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.
     
    Staining
    1. Wash sections in dH2O three times for 5 min each.
    2. Incubate sections in 3% hydrogen peroxide for 10 min.
    3. Wash sections in dH2O two times for 5 min each.
    4. Wash sections in wash buffer for 5 min.
    5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.
    6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.
    7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.
    8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.
    9. Wash sections three times with wash buffer for 5 min each.
    10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.
    11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.
    12. Immerse slides in dH2O.
    13. If desired, counterstain sections with hematoxylin.
    14. Wash sections in dH2O two times for 5 min each.
    15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.
    16. Mount sections with coverslips and mounting medium.
     

    Datasheet & SDS

    生物学的記述

    Specificity
    Phospho-Tuberin/TSC2 (Thr1462) Antibody (Rabbit mAb) [F15L14] detects endogenous levels of total Tuberin/TSC2 protein only when it is phosphorylated at Thr1462.
    タンパク質の局在
    細胞質、リソソーム、細胞内膜系
    Uniprot ID
    P49815
    Clone
    F15L14
    Synonym(s)
    TSC4, TSC2, Tuberin, Tuberous sclerosis 2 protein
    Background
    Phospho‑Tuberin/TSC2 (Thr1462) represents a key regulated form of the TSC2 tumor suppressor, which functions with TSC1 in the tuberous sclerosis complex to restrain mTORC1‑dependent anabolic signaling and cell growth by acting as a GAP toward the small GTPase Rheb and thereby limiting phosphorylation of downstream effectors such as S6K1 and 4E‑BP1. Tuberin contains multiple regulatory domains and phosphorylation sites that integrate growth factor and stress signals, and Thr1462 lies within an Akt consensus motif in the C‑terminal region, where phosphorylation modulates the stability and activity of the TSC1–TSC2 complex and its ability to suppress mTORC1 signaling. Activation of the PI3K–Akt pathway by mitogenic and insulin signals leads to Akt‑dependent phosphorylation of Tuberin on Thr1462 together with Ser939, which reduces the tumor suppressor function of the TSC complex, permits increased Rheb‑GTP accumulation, and enhances mTORC1‑mediated phosphorylation of 4E‑BP1 and S6K1 that drives cap‑dependent translation, cell growth, and proliferation under nutrient‑replete conditions. Additional kinase pathways, including PKC/MAPK cascades and phosphatidic acid–linked signaling, converge on overlapping and distinct sites in Tuberin, so that Thr1462 phosphorylation participates in a broader phosphorylation code that integrates PI3K‑dependent and PI3K‑independent inputs to fine‑tune inhibition of mTORC1 and to coordinate responses to mitogens, phorbol esters, and other upstream cues. These regulatory events place phospho‑Tuberin (Thr1462) at a central nodal position connecting receptor tyrosine kinase and insulin signaling through PI3K–Akt to mTORC1‑driven biosynthesis and cell‑cycle progression, and make this site a sensitive indicator of growth factor signaling status, nutrient sufficiency, and pharmacologic Akt or mTORC1 inhibition. Tuberous sclerosis complex arises from germline or somatic loss‑of‑function alterations in TSC1 or TSC2, and aberrant control of Tuberin phosphorylation, including dysregulated modification at Thr1462, contributes to inappropriate activation of mTORC1 in hamartomas and tumor cells, supporting uncontrolled cell growth and altered protein synthesis; phosphorylation status at this site is therefore functionally linked to disease‑relevant signaling output and is widely used to monitor pathway engagement in basic research and in therapeutic contexts that target PI3K–Akt–mTOR axis components.
    References

    技術サポート

    ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

    Handling Instructions

    他に質問がある場合は、お気軽にお問い合わせください。

    * 必須

    大学・企業名を記入してください
    名前を記入してください
    電子メール・アドレスを記入してください 有効なメールアドレスを入力してください
    お問い合わせ内容をご入力ください